DDR Inhibitors Summit
Boston, USA
28-30 January 2025
News
Events
JP Morgan Healthcare Conference
San Francisco, USA
13-16 January 2025
MODULATING DNA DAMAGE RESPONSES TO CURE CANCER
DDR Inhibitors Summit
Boston, USA
28-30 January 2025
JP Morgan Healthcare Conference
San Francisco, USA
13-16 January 2025
MODULATING DNA DAMAGE RESPONSES TO CURE CANCER
BVF Partners L.P. Joins Breakpoint’s Investor Syndicate
Biotechnology Value Fund (BVF Partners), a San Francisco-based private investment partnership, has contributed capital in an extension of Breakpoint Therapeutics’ last funding round. Gorjan Hrustanovic, Managing Director at BVF Partners, will join Breakpoint’s Advisory Board as an Observer.
Dr. Juan Jaen Joins Breakpoint’s Advisory Board
Breakpoint welcomed Dr. Juan Jaen to its Advisory Board, adding his nearly 40 years of experience at the forefront of drug discovery and development to the company’s resources. He is Co-Founder, President, and member of the Board of Directors of Arcus Biosciences. Prior to founding Arcus, Juan was Co-Founder of Flexus Biosciences and before that […]
Evotec and venture capital consortium form “Breakpoint Therapeutics GmbH”
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. Breakpoint Therapeutics’ mission is to develop first and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of therapy-resistant cancers.